Zacks.com on MSN2d
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...
Why Is Qiagen N.V. (QGEN) Among the Top CRISPR Stocks to Invest In?
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...
Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – ...
Buy Rating for Crispr Therapeutics AG: Strong Pipeline, Strategic Partnerships, and Financial Stability Drive Confidence
Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...